Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis

Vascular endothelial growth factor (VEGF) is a multifunctional cytokine that increases microvascular permeability and directly stimulates endothelial cell growth and angiogenesis. Recent evidence suggests that the genetic regulation of angiogenesis is also of crucial importance and that oncogenes an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lung cancer 2001-12, Vol.34, p.S59-S64
Hauptverfasser: Niklińska, Wiesława, Burzykowski, Tomasz, Chyczewski, Lech, Nikliński, Jacek
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S64
container_issue
container_start_page S59
container_title Lung cancer
container_volume 34
creator Niklińska, Wiesława
Burzykowski, Tomasz
Chyczewski, Lech
Nikliński, Jacek
description Vascular endothelial growth factor (VEGF) is a multifunctional cytokine that increases microvascular permeability and directly stimulates endothelial cell growth and angiogenesis. Recent evidence suggests that the genetic regulation of angiogenesis is also of crucial importance and that oncogenes and tumor suppressor genes can regulate it. The aim of this study was to determine the prognostic value of VEGF and its possible asscociation with p53-gene mutation in 89 stage I-IIIa surgically treated NSCLC patients. DNA sequencing of the p53 gene (exons 5–8) showed 40 mutations (45%). Among the 89 NSCLC patients, immunoreactivity for VEGF was weakly, moderately and strongly positive in 35 (39%), 36 (40%) and 18 (20%) cases, respectively. A strong, statistically significant association was found between the presence of a p53 gene mutation and expression of VEGF ( P
doi_str_mv 10.1016/S0169-5002(01)00346-4
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72296806</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169500201003464</els_id><sourcerecordid>72296806</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-7de46a2ab5c032bb6e7a077665c1f77a12c3060a63ae40dab95d912c209985533</originalsourceid><addsrcrecordid>eNqFkcFu1DAQhi0EotvCI4B8AXUPgbGd2BsuCK22BWkFhwJXa-I4W6PE3tpJW56CV8bpruiRy1gaffPP-P8JecXgHQMm31_lUhcVAD8HtgQQpSzKJ2TBVooXKyH4U7L4h5yQ05R-ATDFoH5OThhTHFQpFuTP5n4fbUoueBo6eovJTD1Gan0bxmvbO-zpLoa78Zp2aMYQ6fnPzeXFkjpPffBFGrDvqbG59JPfUYPe2Ax9vVpv18sPFFMKxuE469-5rLKvBN1Zb-kwjYc2-pbuY9j5kFx6QZ512Cf78viekR8Xm-_rz8X22-WX9adtYUTNxkK1tpTIsakMCN400ioEpaSsDOuUQsaNAAkoBdoSWmzqqq1zk0Ndr6pKiDPy9qCbN99MNo16cGn-BnobpqQV57VcgcxgdQBNDClF2-l9dAPG35qBnpPQD0no2WYNTD8kocs89_q4YGoG2z5OHa3PwJsjkD3HvovZOZceuZJVgtXzAR8PnM123DobdTLOZpdbF60ZdRvcf075C8slpQE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72296806</pqid></control><display><type>article</type><title>Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Niklińska, Wiesława ; Burzykowski, Tomasz ; Chyczewski, Lech ; Nikliński, Jacek</creator><creatorcontrib>Niklińska, Wiesława ; Burzykowski, Tomasz ; Chyczewski, Lech ; Nikliński, Jacek</creatorcontrib><description>Vascular endothelial growth factor (VEGF) is a multifunctional cytokine that increases microvascular permeability and directly stimulates endothelial cell growth and angiogenesis. Recent evidence suggests that the genetic regulation of angiogenesis is also of crucial importance and that oncogenes and tumor suppressor genes can regulate it. The aim of this study was to determine the prognostic value of VEGF and its possible asscociation with p53-gene mutation in 89 stage I-IIIa surgically treated NSCLC patients. DNA sequencing of the p53 gene (exons 5–8) showed 40 mutations (45%). Among the 89 NSCLC patients, immunoreactivity for VEGF was weakly, moderately and strongly positive in 35 (39%), 36 (40%) and 18 (20%) cases, respectively. A strong, statistically significant association was found between the presence of a p53 gene mutation and expression of VEGF ( P&lt;0.001). The positive result of the p53 mutation increased the odds of observing a higher level of VEGF expression approximately 9.5 times (95% confidence interval: [3.44, 25.89]). In the univariate analysis of survival, increasing levels of VEGF expression were associated with poor prognosis ( P&lt;0.001 for trend). In the multivariate analysis, after adjusting for the presence of a p53-gene mutation, gender, TNM stage and histological type, the prognostic effect of VEGF expression level was marginally non-significant ( P=0.077). When the two-category quantification of the VEGF level was considered (low vs. intermediate/high), a marginally significant ( P=0.024), unfavorable effect of intermediate/high levels of VEGF expression, independent of the effect of the presence of a p53-gene mutation, was found. In conclusion, we found that the p53 mutation was closely related to VEGF expression. Additionally, we observed that an intermediate/high expression of VEGF might be a useful indicator of prognosis in NSCLC. This latter conjecture, suggested by an analysis of the data, ought however, to be independently verified in further studies.</description><identifier>ISSN: 0169-5002</identifier><identifier>EISSN: 1872-8332</identifier><identifier>DOI: 10.1016/S0169-5002(01)00346-4</identifier><identifier>PMID: 11720743</identifier><identifier>CODEN: LUCAE5</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Biological and medical sciences ; Biomarkers, Tumor - analysis ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - physiopathology ; Diagnosis ; DNA Mutational Analysis ; Endothelial Growth Factors - biosynthesis ; Female ; Gene Expression Regulation, Neoplastic ; Genes, p53 - genetics ; Humans ; Lung cancer ; Lung Neoplasms - genetics ; Lung Neoplasms - physiopathology ; Lymphokines - biosynthesis ; Male ; Medical sciences ; Neoplasm Staging ; p53 ; Pneumology ; Prognosis ; Sequence Analysis, DNA ; Survival Analysis ; Tumors of the respiratory system and mediastinum ; Vascular Endothelial Growth Factor A ; Vascular Endothelial Growth Factors ; VEGF</subject><ispartof>Lung cancer, 2001-12, Vol.34, p.S59-S64</ispartof><rights>2001 Elsevier Science Ireland Ltd</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-7de46a2ab5c032bb6e7a077665c1f77a12c3060a63ae40dab95d912c209985533</citedby><cites>FETCH-LOGICAL-c391t-7de46a2ab5c032bb6e7a077665c1f77a12c3060a63ae40dab95d912c209985533</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0169-5002(01)00346-4$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,3549,23929,23930,25139,27923,27924,45994</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14153196$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11720743$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Niklińska, Wiesława</creatorcontrib><creatorcontrib>Burzykowski, Tomasz</creatorcontrib><creatorcontrib>Chyczewski, Lech</creatorcontrib><creatorcontrib>Nikliński, Jacek</creatorcontrib><title>Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis</title><title>Lung cancer</title><addtitle>Lung Cancer</addtitle><description>Vascular endothelial growth factor (VEGF) is a multifunctional cytokine that increases microvascular permeability and directly stimulates endothelial cell growth and angiogenesis. Recent evidence suggests that the genetic regulation of angiogenesis is also of crucial importance and that oncogenes and tumor suppressor genes can regulate it. The aim of this study was to determine the prognostic value of VEGF and its possible asscociation with p53-gene mutation in 89 stage I-IIIa surgically treated NSCLC patients. DNA sequencing of the p53 gene (exons 5–8) showed 40 mutations (45%). Among the 89 NSCLC patients, immunoreactivity for VEGF was weakly, moderately and strongly positive in 35 (39%), 36 (40%) and 18 (20%) cases, respectively. A strong, statistically significant association was found between the presence of a p53 gene mutation and expression of VEGF ( P&lt;0.001). The positive result of the p53 mutation increased the odds of observing a higher level of VEGF expression approximately 9.5 times (95% confidence interval: [3.44, 25.89]). In the univariate analysis of survival, increasing levels of VEGF expression were associated with poor prognosis ( P&lt;0.001 for trend). In the multivariate analysis, after adjusting for the presence of a p53-gene mutation, gender, TNM stage and histological type, the prognostic effect of VEGF expression level was marginally non-significant ( P=0.077). When the two-category quantification of the VEGF level was considered (low vs. intermediate/high), a marginally significant ( P=0.024), unfavorable effect of intermediate/high levels of VEGF expression, independent of the effect of the presence of a p53-gene mutation, was found. In conclusion, we found that the p53 mutation was closely related to VEGF expression. Additionally, we observed that an intermediate/high expression of VEGF might be a useful indicator of prognosis in NSCLC. This latter conjecture, suggested by an analysis of the data, ought however, to be independently verified in further studies.</description><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - physiopathology</subject><subject>Diagnosis</subject><subject>DNA Mutational Analysis</subject><subject>Endothelial Growth Factors - biosynthesis</subject><subject>Female</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Genes, p53 - genetics</subject><subject>Humans</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - physiopathology</subject><subject>Lymphokines - biosynthesis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neoplasm Staging</subject><subject>p53</subject><subject>Pneumology</subject><subject>Prognosis</subject><subject>Sequence Analysis, DNA</subject><subject>Survival Analysis</subject><subject>Tumors of the respiratory system and mediastinum</subject><subject>Vascular Endothelial Growth Factor A</subject><subject>Vascular Endothelial Growth Factors</subject><subject>VEGF</subject><issn>0169-5002</issn><issn>1872-8332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFu1DAQhi0EotvCI4B8AXUPgbGd2BsuCK22BWkFhwJXa-I4W6PE3tpJW56CV8bpruiRy1gaffPP-P8JecXgHQMm31_lUhcVAD8HtgQQpSzKJ2TBVooXKyH4U7L4h5yQ05R-ATDFoH5OThhTHFQpFuTP5n4fbUoueBo6eovJTD1Gan0bxmvbO-zpLoa78Zp2aMYQ6fnPzeXFkjpPffBFGrDvqbG59JPfUYPe2Ax9vVpv18sPFFMKxuE469-5rLKvBN1Zb-kwjYc2-pbuY9j5kFx6QZ512Cf78viekR8Xm-_rz8X22-WX9adtYUTNxkK1tpTIsakMCN400ioEpaSsDOuUQsaNAAkoBdoSWmzqqq1zk0Ndr6pKiDPy9qCbN99MNo16cGn-BnobpqQV57VcgcxgdQBNDClF2-l9dAPG35qBnpPQD0no2WYNTD8kocs89_q4YGoG2z5OHa3PwJsjkD3HvovZOZceuZJVgtXzAR8PnM123DobdTLOZpdbF60ZdRvcf075C8slpQE</recordid><startdate>20011201</startdate><enddate>20011201</enddate><creator>Niklińska, Wiesława</creator><creator>Burzykowski, Tomasz</creator><creator>Chyczewski, Lech</creator><creator>Nikliński, Jacek</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20011201</creationdate><title>Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis</title><author>Niklińska, Wiesława ; Burzykowski, Tomasz ; Chyczewski, Lech ; Nikliński, Jacek</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-7de46a2ab5c032bb6e7a077665c1f77a12c3060a63ae40dab95d912c209985533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - physiopathology</topic><topic>Diagnosis</topic><topic>DNA Mutational Analysis</topic><topic>Endothelial Growth Factors - biosynthesis</topic><topic>Female</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Genes, p53 - genetics</topic><topic>Humans</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - physiopathology</topic><topic>Lymphokines - biosynthesis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neoplasm Staging</topic><topic>p53</topic><topic>Pneumology</topic><topic>Prognosis</topic><topic>Sequence Analysis, DNA</topic><topic>Survival Analysis</topic><topic>Tumors of the respiratory system and mediastinum</topic><topic>Vascular Endothelial Growth Factor A</topic><topic>Vascular Endothelial Growth Factors</topic><topic>VEGF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Niklińska, Wiesława</creatorcontrib><creatorcontrib>Burzykowski, Tomasz</creatorcontrib><creatorcontrib>Chyczewski, Lech</creatorcontrib><creatorcontrib>Nikliński, Jacek</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Lung cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Niklińska, Wiesława</au><au>Burzykowski, Tomasz</au><au>Chyczewski, Lech</au><au>Nikliński, Jacek</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis</atitle><jtitle>Lung cancer</jtitle><addtitle>Lung Cancer</addtitle><date>2001-12-01</date><risdate>2001</risdate><volume>34</volume><spage>S59</spage><epage>S64</epage><pages>S59-S64</pages><issn>0169-5002</issn><eissn>1872-8332</eissn><coden>LUCAE5</coden><abstract>Vascular endothelial growth factor (VEGF) is a multifunctional cytokine that increases microvascular permeability and directly stimulates endothelial cell growth and angiogenesis. Recent evidence suggests that the genetic regulation of angiogenesis is also of crucial importance and that oncogenes and tumor suppressor genes can regulate it. The aim of this study was to determine the prognostic value of VEGF and its possible asscociation with p53-gene mutation in 89 stage I-IIIa surgically treated NSCLC patients. DNA sequencing of the p53 gene (exons 5–8) showed 40 mutations (45%). Among the 89 NSCLC patients, immunoreactivity for VEGF was weakly, moderately and strongly positive in 35 (39%), 36 (40%) and 18 (20%) cases, respectively. A strong, statistically significant association was found between the presence of a p53 gene mutation and expression of VEGF ( P&lt;0.001). The positive result of the p53 mutation increased the odds of observing a higher level of VEGF expression approximately 9.5 times (95% confidence interval: [3.44, 25.89]). In the univariate analysis of survival, increasing levels of VEGF expression were associated with poor prognosis ( P&lt;0.001 for trend). In the multivariate analysis, after adjusting for the presence of a p53-gene mutation, gender, TNM stage and histological type, the prognostic effect of VEGF expression level was marginally non-significant ( P=0.077). When the two-category quantification of the VEGF level was considered (low vs. intermediate/high), a marginally significant ( P=0.024), unfavorable effect of intermediate/high levels of VEGF expression, independent of the effect of the presence of a p53-gene mutation, was found. In conclusion, we found that the p53 mutation was closely related to VEGF expression. Additionally, we observed that an intermediate/high expression of VEGF might be a useful indicator of prognosis in NSCLC. This latter conjecture, suggested by an analysis of the data, ought however, to be independently verified in further studies.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>11720743</pmid><doi>10.1016/S0169-5002(01)00346-4</doi></addata></record>
fulltext fulltext
identifier ISSN: 0169-5002
ispartof Lung cancer, 2001-12, Vol.34, p.S59-S64
issn 0169-5002
1872-8332
language eng
recordid cdi_proquest_miscellaneous_72296806
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Biological and medical sciences
Biomarkers, Tumor - analysis
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - physiopathology
Diagnosis
DNA Mutational Analysis
Endothelial Growth Factors - biosynthesis
Female
Gene Expression Regulation, Neoplastic
Genes, p53 - genetics
Humans
Lung cancer
Lung Neoplasms - genetics
Lung Neoplasms - physiopathology
Lymphokines - biosynthesis
Male
Medical sciences
Neoplasm Staging
p53
Pneumology
Prognosis
Sequence Analysis, DNA
Survival Analysis
Tumors of the respiratory system and mediastinum
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
VEGF
title Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T20%3A38%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20vascular%20endothelial%20growth%20factor%20(VEGF)%20in%20non-small%20cell%20lung%20cancer%20(NSCLC):%20association%20with%20p53%20gene%20mutation%20and%20prognosis&rft.jtitle=Lung%20cancer&rft.au=Nikli%C5%84ska,%20Wies%C5%82awa&rft.date=2001-12-01&rft.volume=34&rft.spage=S59&rft.epage=S64&rft.pages=S59-S64&rft.issn=0169-5002&rft.eissn=1872-8332&rft.coden=LUCAE5&rft_id=info:doi/10.1016/S0169-5002(01)00346-4&rft_dat=%3Cproquest_cross%3E72296806%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72296806&rft_id=info:pmid/11720743&rft_els_id=S0169500201003464&rfr_iscdi=true